Showing results (261-270 of 406) with videos related to
Sort By:
Pageof 41
Cancer Immunology, Immunotherapy : CII|April 24, 2025
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cellsElias Brauneck, Leon-Gordian Leonhardt, Anne Marie Assemissen, et al.Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.Oncotarget|November 22, 2017
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trialMichael Schmitt, Angela G Hückelhoven, Michael Hundemer, et al.British Journal of Cancer|September 28, 2019
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myelomaHeinz Ludwig, Wolfram Poenisch, Stefan Knop, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factorKatharina Wagner, Frederik Damm, Gudrun Göhring, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 16, 2017
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing CommitteeSarah A Holstein, Hervé Avet-Loiseau, Theresa Hahn, et al.Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple MyelomaMaría-Victoria Mateos, Ajai Chari, Saad Z Usmani, et al.Cancer Research|July 23, 2013
SOX2 expression associates with stem cell state in human ovarian carcinomaPetra M Bareiss, Anna Paczulla, Hui Wang, et al.Leukemia & Lymphoma|April 29, 2016
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantationKatja Weisel, Chantal Doyen, Meletios Dimopoulos, et al.Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.Pageof 41